Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) reached a new 52-week low on Friday . The stock traded as low as $16.48 and last traded at $16.78, with a volume of 173232 shares. The stock had previously closed at $17.05.
Wall Street Analyst Weigh In
Several research firms recently commented on AAPG. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research reiterated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $46.43.
Get Our Latest Stock Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Performance
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million during the quarter. On average, equities analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -0.96 earnings per share for the current year.
Institutional Trading of Ascentage Pharma Group International
Several large investors have recently added to or reduced their stakes in AAPG. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth $383,000. XY Capital Ltd increased its stake in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG raised its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the second quarter valued at $391,000.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.
Founded in 2008 by biotechnology entrepreneur Dr.
Featured Articles
- Five stocks we like better than Ascentage Pharma Group International
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
